grew from the chemical group when it was founded in 1928 to a general medicine company, and then transformed into an innovative biomedical company. USSIB worked hard on the "professional track" of " nervous system and immune system", investing more than 25% of its sales each year to continuously develop innovative therapies and drugs, becoming a global leader in anti-epilepsy and being unique in the field of immune system.
In the early 1990s, Useby entered the Chinese market, registered in Pudong in 2006, and was awarded a cross-border regional headquarters certificate in 2021. Based in Shanghai, Youshibi has continuously introduced global innovation achievements and cooperated with multiple parties to play an active role in promoting the innovative development of biopharmaceutical industry .
YouShibi China General Manager Wu Xin said: "Pudong's good business environment and policies to attract talents and support innovation provide strong support for the sustainable development of enterprises and also provides fertile ground for the transformation and upgrading of the biopharmaceutical industry."
One of the world's seven major clinical development centers have been established in Shanghai
Deep farming Open Innovation
In early 2022, USB, an anti-epileptic product Staccato® (alprazolam inhaled powder), which is in the global phase 3 clinical stage, was recognized as "breakthrough therapy" in China. This is the first time that the new drug has obtained breakthrough therapy certification among global regulatory agencies. It is expected to become the first innovative therapy to quickly terminate active epilepsy seizures on demand and one-time treatment. It will also greatly accelerate its clinical development and application for marketing, benefiting patients in China and even around the world.
reporter learned that the USB China headquarters, registered in Shanghai Pudong , is also one of the seven largest clinical development centers in the world. The world-class R&D team is rooted here, carrying out multiple global synchronous multi-center clinical development projects, and pays attention to and seeks early R&D partners in China's innovative hot spot.
Wu Xin introduced that as an innovative biopharmaceutical company, Youshibi has always actively carried out multi-party cooperation to expand the value of patients and promote industrial upgrading in areas of focus. In 2007, Ushibi took the lead in introducing the first new anti-epileptic drug Kaipulan® into China. Over the past 15 years, it has joined hands with industry experts, associations and foundations such as China Anti-epileptic Association to help improve the overall diagnosis and treatment level of epilepsy from cities to rural areas, improve the management of epilepsy patients throughout the course of the disease and the quality of life of families. Through a series of corporate social responsibility projects, it has improved the popular science education of epilepsy and corrected the society's wrong perception of the disease, hoping to create a more friendly environment for patients.
promotes digital innovation
cooperates with multi-party cooperation to create a digital pharmaceutical ecosystem
Youshibi is one of the first multinational pharmaceutical companies in the industry to cooperate with leaders in the digital ecosystem. At the beginning of market changes, it has begun to explore innovative ways to improve patient experience and long-term management of chronic diseases through digitalization. It has successively cooperated with partners such as JD Health , Ali Health , Tencent Smart Pharmaceuticals, and Magnesium Health.
reporter learned that at the beginning of the outbreak of the epidemic in 2020, USB and JD Health completed the construction and launch of the first single-disease disease museum within one month to ensure the accessibility of treatment for chronic disease patients. In order to facilitate doctor-patient communication and strengthen disease management, USSIB has joined hands with Alibaba Health to build a "one-stop service platform for cloud diagnosis and treatment and medication", providing patients with chronic diseases with smarter and more comprehensive closed-loop services and improving patient experience.
In addition, in order to better provide help to patients with chronic diseases and gain in-depth understanding of patient needs, Youshibi and Tencent Smart Medicine have jointly created the first "Epilepsy Circle" for children with epilepsy to provide disease science popularization for children with epilepsy and parents. "I hope that all patients in need can use the medicine. Ushibi and Commercial Insurance partners will work together to launch a patient support program, so that more patients in need can benefit from the unique value of the product and further improve the accessibility and affordability of the drug." Wu Xin said.
1. digital transformation has penetrated into all aspects of daily operations of Youshibi. As early as the beginning of rapid market changes, USB reintegrated finance, marketing performance management, marketing and other departments into I2I departments (Insight to Impact), generating high-quality data and insights that USB can share globally.
With the help of the good business environment in Pudong
to enhance the possibility of innovative drugs being first released in China
This year, USSIB will debut at the 5th China International Import Expo on this open platform to show everyone global innovation achievements. These innovative drugs cover the nervous system, immune system, bone health and rare disease fields, including Staccato® (alprazolam inhalation powder) that was recognized as a "breakthrough treatment" in China at the beginning of this year.
After the release of the "Opinions of the Central Committee of the Communist Party of China and the State Council on Supporting the High-level Reform and Opening-up of Pudong New Area to Build a Leading Zone for Socialist Modernization Construction", Wu Xin was delighted to see that the "Opinions" emphasized the strengthening of the protection of corporate intellectual property rights, which is a good guarantee for sustainable development for listed companies, especially intellectual property-intensive biopharmaceutical companies.
"China is one of the key markets of Ushibi in the world. We are very much looking forward to Pudong increasing its support for drug research and development, especially early research and development, and further enhancing the possibility of innovative drugs developed simultaneously globally in China. At the same time, we also hope that the Pudong headquarters economy, the 'golden business card', will become more and more dazzling, give full play to the role of the leading zone, and drive the economy to a higher level of development." Wu Xin said.
Text: Yang Zhenying
Edited by Wu Yan
* Please indicate the official WeChat
* Please indicate the reprinting from Pudong Release official WeChat
